Data on:
Mirati Therapeutics
Bookmark
ShareMirati Therapeutics is a company. It is in San Diego, the United States and it has a male CEO called David D. Meek. It was founded in 2013 and is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- governance score (ESG): Try Pro to see estimate
- CEO gender: male
- CEO: David D. Meek
- state: CA
- social score (ESG): Try Pro to see estimate
- revenues: 72.8M $
- employees: 413 people
- sector: Health Care
- industry: Biotechnology
- ESG score: Try Pro to see estimate
- foundation year: 2013
- city: San Diego
- country: United States
- environmental score (ESG): Try Pro to see estimate
See more facts
Extract data
Download datasets about Mirati Therapeutics:
Dataset of stocks from Mirati Therapeutics:
Mirati Therapeutics is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in David D. Meek, companies in San Diego and 3,456,835 companies in our database.
Talking Points
- Global Biopharmaceutical CompanyBristol Myers Squibb
- Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
- Our mission is to discover, design & deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. https://t.co/nXoCkyY6VT
- 201-500 employees Headquarters San Diego, California Type Public Company Founded 2013 Locations Primary 3545 Cray Ct San Diego, California 92121, US Get directions Employees at Mirati Therapeutics...
- Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
